Sarah Hoit - Biovie Chief Officer
| BIVI Stock | USD 3.05 0.06 1.93% |
Insider
Sarah Hoit is Chief Officer of Biovie Inc
| Age | 56 |
| Address | 680 West Nye Lane, Carson City, NV, United States, 89703 |
| Phone | 775 888 3162 |
| Web | https://bioviepharma.com |
Biovie Management Efficiency
The company has return on total asset (ROA) of (0.6669) % which means that it has lost $0.6669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0826) %, meaning that it created substantial loss on money invested by shareholders. Biovie's management efficiency ratios could be used to measure how well Biovie manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.38. The current Return On Capital Employed is estimated to decrease to -2.13. As of now, Biovie's Non Current Assets Total are increasing as compared to previous years. The Biovie's current Other Assets is estimated to increase to 5,509, while Non Currrent Assets Other are projected to decrease to 0.00.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Lewicki | Mereo BioPharma Group | 72 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Christine CPA | Mereo BioPharma Group | 43 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Prof MD | Hookipa Pharma | 80 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.08 | ||||
| Return On Asset | -0.67 |
Biovie Inc Leadership Team
Elected by the shareholders, the Biovie's board of directors comprises two types of representatives: Biovie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biovie. The board's role is to monitor Biovie's management team and ensure that shareholders' interests are well served. Biovie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biovie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MD, Executive Officer | ||
| Cuong MBA, CEO President | ||
| Clarence Ahlem, Senior Operations | ||
| Joanne CPA, Treasurer CFO | ||
| Denise Smith, Senior Development | ||
| Sarah Hoit, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| Penelope Markham, Chief Scientific Officer | ||
| Christopher Reading, Senior Program |
Biovie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biovie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.08 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 37.89 M | ||||
| Shares Outstanding | 17.77 M | ||||
| Shares Owned By Insiders | 13.69 % | ||||
| Shares Owned By Institutions | 9.98 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Earning | 18.12 X | ||||
| Price To Book | 3.85 X | ||||
| EBITDA | (31.95 M) |
Currently Active Assets on Macroaxis
When determining whether Biovie Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biovie's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biovie Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biovie Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biovie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biovie. If investors know Biovie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.08) | Return On Assets (0.67) | Return On Equity (2.08) |
The market value of Biovie Inc is measured differently than its book value, which is the value of Biovie that is recorded on the company's balance sheet. Investors also form their own opinion of Biovie's value that differs from its market value or its book value, called intrinsic value, which is Biovie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biovie's market value can be influenced by many factors that don't directly affect Biovie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biovie's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biovie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biovie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.